Raybow Pharma is your Global|Green|EHS Focused|R&D Centric CDMO.

Built in 2009 and purchased from Novartis in the fall of 2019, Raybow Suzhou is an established and reputable API manufacturing facility and provides a number of lifesaving medicines to patients around the world.

The Suzhou site has room to expand further and employs leading edge waste treatment and recirculation technologies.

Contact Us

Raybow Suzhou

L
Hydrogenator (X3)
L
Pilot Production - Max Reactor
L
Max Commercial Reactor